Screener
Iovance Biotherapeutics, Inc. IOVA Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $99.31M+65.7% | $71.43M+44.8% | $86.77M+17.7% | $67.46M+15.2% | $59.95M+92.7% | ||
| $43.6M-10.8% | $42.5M-0.5% | $43.11M+14.1% | $38.48M+22.1% | $48.88M+55.8% | ||
| $55.72M+403% | $28.93M+338% | $43.66M+21.6% | $28.98M+7.2% | $11.07M+4,326% | ||
| 56.1%+37.6pp | 40.5%+27.1pp | 50.3%+1.6pp | 43%-3.2pp | 18.5%+19.3pp | ||
| $58.85M-24.5% | $62.49M-17.7% | $71.2M+0.3% | $75.17M+12.1% | $77.93M+25.5% | ||
| $39.27M+4.5% | $38.95M-11.1% | $36.4M-14.0% | $34.56M-12.2% | $37.57M-5.1% | ||
| $151.22M-13.0% | $152.47M-10.6% | $160.23M0.0% | $162.36M+10.0% | $173.73M+30.6% | ||
| -$51.91M+54.4% | -$81.04M+33.1% | -$73.46M+15.1% | -$94.9M-6.6% | -$113.77M-11.6% | ||
| -52.3%+138pp | -113.5%+132pp | -84.7%+32.8pp | -140.7%+11.4pp | -189.8%+138pp | ||
| -$48.69M+55.6% | -$79.71M+32.4% | -$71.72M+6.9% | -$93.66M-10.1% | -$109.67M-11.3% | ||
| -$1.37M-169% | -$665K+63.8% | $0— | -$2.41M-58.2% | $1.99M+236% | ||
| -$47.32M+57.6% | -$79.05M+32.0% | -$71.9M+8.5% | -$91.25M-9.2% | -$111.66M-15.0% | ||
| -47.6%+139pp | -110.7%+125pp | -82.9%+23.7pp | -135.3%+7.4pp | -186.2%+126pp | ||
| -$0.11+66.7% | -$0.19+47.2% | —— | —— | -$0.33+2.9% | ||
| -$48.12M+56.4% | -$78.22M+34.1% | -$69.74M+16.3% | -$91.71M-6.6% | -$110.37M-11.6% | ||
| -48.5%+136pp | -109.5%+131pp | -80.4%+32.7pp | -136%+11.0pp | -184.1%+134pp | ||
| -$51.91M+54.4% | -$81.04M+33.1% | -$73.46M+15.1% | -$94.9M-6.6% | -$113.77M-11.6% |
FAQ
- What is Iovance Biotherapeutics, Inc.'s revenue?
- Iovance Biotherapeutics, Inc. (IOVA) generated $325.0M in revenue over the trailing twelve months, up 34.5% year over year.
- Is Iovance Biotherapeutics, Inc. profitable?
- Iovance Biotherapeutics, Inc. is not currently profitable: it reported a net loss of $289.5M over the trailing twelve months, a -89.1% net margin.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Gross margin is 48.4% and operating margin is -92.7%, with a -89.1% net margin.
- What is Iovance Biotherapeutics, Inc.'s earnings per share?
- Iovance Biotherapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.99.
- Where does Iovance Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
